Acute sulfonylurea therapy at disease onset can cause permanent remission of K ATP-induced diabetes

Diabetes

Volumn 60, Issue 10, 2011, Pages 2515-2522

  Remedi, Maria Sara ^a   Agapova, Sophia E ^a   Vyas, Arpita K ^a   Hruz, Paul W ^a   Nichols, Colin G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLIBENCLAMIDE; GLUCOSE; SULFONYLUREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; GLUCOSE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; ISLETS OF LANGERHANS; KATP CHANNELS; MICE; MICE, TRANSGENIC; MUTATION; SULFONYLUREA COMPOUNDS;

EID: 80053422246     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-0538     Document Type: Article

References (44)

1. Clement JP 4th, Kunjilwar K, Gonzalez G, et al. Association and stoichiometry of K(ATP) channel subunits. Neuron 1997;18:827-838 (Pubitemid 27232792)
2. Inagaki N, Gonoi T, Clement JP 4th, et al. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 1995;270:1166-1170
3. Shyng S, Nichols CG. Octameric stoichiometry of the KATP channel complex. J Gen Physiol 1997;110:655-664 (Pubitemid 27524606)
4. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004;350:1838-1849 (Pubitemid 38917250)
5. Hamilton-Shield JP. Overview of neonatal diabetes. Endocr Dev 2007;12:12-23
6. Polak M, Cavé H. Neonatal diabetes mellitus: a disease linked to multiple mechanisms. Orphanet J Rare Dis 2007;2:12
7. Sperling MA. The genetic basis of neonatal diabetes mellitus. Pediatr Endocrinol Rev 2006;4(Suppl. 1):71-75 (Pubitemid 46224449)
8. Vaxillaire M, Populaire C, Busiah K, et al. Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes 2004;53:2719-2722 (Pubitemid 39299285)
9. Flanagan SE, Clauin S, Bellanné-Chantelot C, et al. Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat 2009;30:170-180
10. Ashcroft FM, Gribble FM. ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia 1999;42:903-919 (Pubitemid 29369597)
11. Nichols CG. KATP channels as molecular sensors of cellular metabolism. Nature 2006;440:470-476
12. Remedi MS, Koster JC. K(ATP) channelopathies in the pancreas. Pflugers Arch 2010;460:307-320
13. Gloyn AL, Reimann F, Girard C, et al. Relapsing diabetes can result from moderately activating mutations in KCNJ11. Hum Mol Genet 2005;14:925-934 (Pubitemid 40533103)
14. Flanagan SE, Patch AM, Mackay DJ, et al. Mutations in ATP-sensitive K+ channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes 2007;56:1930-1937 (Pubitemid 47025462)
15. Babenko AP, Polak M, Cavé H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006;355:456-466 (Pubitemid 44162273)
16. Vaxillaire M, Dechaume A, Busiah K, et al.; SUR1-Neonatal Diabetes Study Group. New ABCC8 mutations in relapsing neonatal diabetes and clinical features. Diabetes 2007;56:1737-1741 (Pubitemid 46842623)
17. Patch AM, Flanagan SE, Boustred C, Hattersley AT, Ellard S. Mutations in the ABCC8 gene encoding the SUR1 subunit of the KATP channel cause transient neonatal diabetes, permanent neonatal diabetes or permanent diabetes diagnosed outside the neonatal period. Diabetes Obes Metab 2007;9(Suppl. 2):28-39 (Pubitemid 47543124)
18. Klupa T, Kowalska I, Wyka K, et al. Mutations in the ABCC8 (SUR1 subunit of the K(ATP) channel) gene are associated with a variable clinical phenotype. Clin Endocrinol (Oxf) 2009;71:358-362
19. Yorifuji T, Nagashima K, Kurokawa K, et al. The C42R mutation in the Kir6.2 (KCNJ11) gene as a cause of transient neonatal diabetes, childhood diabetes, or later-onset, apparently type 2 diabetes mellitus. J Clin Endocrinol Metab 2005;90:3174-3178 (Pubitemid 41014271)
20. Koster JC, Marshall BA, Ensor N, Corbett JA, Nichols CG. Targeted overactivity of beta cell K(ATP) channels induces profound neonatal diabetes. Cell 2000;100:645-654
21. Remedi MS, Kurata HT, Scott A, et al. Secondary consequences of beta cell inexcitability: identification and prevention in a murine model of K(ATP)-induced neonatal diabetes mellitus. Cell Metab 2009; 9:140-151
22. Zhang H, Fujitani Y, Wright CV, Gannon M. Efficient recombination in pancreatic islets by a tamoxifen-inducible Cre-recombinase. Genesis 2005;42:210-217 (Pubitemid 41099681)
23. Wicksteed B, Brissova M, Yan W, et al. Conditional gene targeting in mouse pancreatic b-cells: analysis of ectopic Cre transgene expression in the brain. Diabetes 2010;59:3090-3098
24. Remedi MS, Nichols CG. Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells. PLoS Med 2008;5:e206
25. Sagen JV, Raeder H, Hathout E, et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004;53:2713-2718 (Pubitemid 39299284)
26. Pearson ER, Flechtner I, Njølstad PR, et al.; Neonatal Diabetes International Collaborative Group. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006;355:467-477 (Pubitemid 44162274)
27. Shimomura K, Hörster F, De Wet H, et al. A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain. Neurology 2007;69:1342-1349 (Pubitemid 47482448)
28. Batra CM, Gupta N, Atwal G, Gupta V. Transient neonatal diabetes due to activating mutation in the ABCC8 gene encoding SUR1. Indian J Pediatr 2009;76:1169-1172
29. Loomba-Albrecht LA, Glaser NS, Styne DM, Bremer AA. An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus. Clin Ther 2009;31:816-820
30. Martín-Frías M, Colino E, Pérez de Nanclares G, Alonso M, Ros P, Barrio R. Glibenclamide treatment in relapsed transient neonatal diabetes as a result of a KCNJ11 activating mutation (N48D). Diabet Med 2009;26:567-569
31. Flechtner I, Vaxillaire M, Cavé H, Scharfmann R, Froguel P, Polak M. Diabetes in very young children and mutations in the insulin-secreting cell potassium channel genes: therapeutic consequences. Endocr Dev 2007;12:86-98
32. Masia R, De Leon DD, MacMullen C, McKnight H, Stanley CA, Nichols CG. A mutation in the TMD0-L0 region of sulfonylurea receptor-1 (L225P) causes permanent neonatal diabetes mellitus (PNDM). Diabetes 2007;56:1357-1362 (Pubitemid 46715625)
33. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223 (Pubitemid 9249478)
34. Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 2005;54:2503-2513 (Pubitemid 41233571)
35. Massa O, Iafusco D, D'Amato E, et al.; Early Onset Diabetes Study Group of the Italian Society of Pediatric Endocrinology and Diabetology. KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes. Hum Mutat 2005;25:22-27 (Pubitemid 40075910)
36. Koster JC, Cadario F, Peruzzi C, Colombo C, Nichols CG, Barbetti F. The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy. J Clin Endocrinol Metab 2008;93:1054-1061 (Pubitemid 351398592)
37. Gloyn AL, Siddiqui J, Ellard S. Mutations in the genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat 2006;27:220-231
38. Wambach JA, Marshall BA, Koster JC, White NH, Nichols CG. Successful sulfonylurea treatment of an insulin-naive neonate with diabetes mellitus due to a KCNJ11 mutation. Pediatr Diabetes 2010;11:286-288
39. Hattersley AT, Pearson ER. Minireview: pharmacogenetics and beyond: the interaction of therapeutic response, beta-cell physiology, and genetics in diabetes. Endocrinology 2006;147:2657-2663 (Pubitemid 43764600)
40. Girard CA, Wunderlich FT, Shimomura K, et al. Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest 2009;119:80-90
41. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004;53(Suppl. 3):S16-S21 (Pubitemid 39564517)
42. Riedel MJ, Steckley DC, Light PE. Current status of the E23K Kir6.2 polymorphism: implications for type-2 diabetes. Hum Genet 2005;116:133-145 (Pubitemid 40173997)
43. Nielsen EM, Hansen L, Carstensen B, et al. The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes 2003;52:573-577 (Pubitemid 36173219)
44. + channel activity and is associated with impaired insulin release and enhanced insulin sensitivity in adults with normal glucose tolerance. Diabetes 2009;58:1869-1878